Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acurox Drops Niacin, But King And Acura Need New Study For Reformulation

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms will submit NDA for a revised version of their oxycodone formulation Acurox that offers impediments to abuse by snorting or injection but does not contain niacin, which FDA says is ineffective at preventing oral abuse.

You may also be interested in...



Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility

King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.

Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility

King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.

King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification

With the Skelaxin story "over," King is pushing ahead with plans to resubmit abuse-deterrent opioids Remoxy and Acurox for FDA approval and fine-tuning its sales force to improve performance of Embeda.

Related Content

Topics

UsernamePublicRestriction

Register

PS070702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel